Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 12/20 | 0.47 |
| ▸ | LTB4R2 | Q9NPC1 | 10/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.39 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.39 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | FOS | P01100 | 1/20 | 0.36 |
| ▸ | JUN | P05412 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26206467 | 0.88 | LTB4R (0.46) | LTB4RLTB4R2ADRB2ADRB1CYSLTR2 | |
| SCHEMBL26206421 | 0.87 | LTB4R (0.44) | LTB4RLTB4R2ADRB2ADRB1CYSLTR2 | |
| SCHEMBL27015526 | 0.87 | LTB4R (0.44) | LTB4RLTB4R2ADRB2ADRB1CYSLTR2 | |
| SCHEMBL26206391 | 0.87 | LTB4R (0.44) | LTB4RLTB4R2ADRB2ADRB1CYSLTR2 | |
| SCHEMBL26206390 | 0.83 | LTB4R (0.40) | LTB4RLTB4R2ADRB2ADRB1CYP2C9 | |
| SCHEMBL26206417 | 0.83 | LTB4R (0.40) | LTB4RLTB4R2ADRB2ADRB1FOS | |
| SCHEMBL22525505 | 0.81 | LTB4R (0.40) | LTB4RLTB4R2ADRB2ADRB1 | |
| SCHEMBL26206404 | 0.80 | LTB4R (0.37) | LTB4RLTB4R2FOSJUN | |
| SCHEMBL26252975 | 0.80 | ADRB2 (0.38) | LTB4RLTB4R2ADRB2ADRB1PPARG | |
| SCHEMBL26206433 | 0.80 | F13A1 (0.37) | LTB4RLTB4R2CYSLTR2CYSLTR1FOS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | LTB4R 2439/4885LTB4R2 2981/4885ADRB2 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.